SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 50,069 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 50,069 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total transaction of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,150.00.

SOPHiA GENETICS Stock Performance

SOPH stock traded up $0.23 during trading on Monday, reaching $5.98. 317,524 shares of the stock were exchanged, compared to its average volume of 175,726. SOPHiA GENETICS SA has a twelve month low of $2.81 and a twelve month high of $6.00. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $501.66 million, a P/E ratio of -11.50 and a beta of 0.98. The stock has a 50 day simple moving average of $5.07 and a 200-day simple moving average of $4.92.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth approximately $50,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS in the fourth quarter valued at $55,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on SOPH shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average target price of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.